



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2025-26/171

January 30, 2026

To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Secretary National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol – BIOCON

Dear Sir/ Madam,

Subject: Buyback of Commercial Papers

This is further to our letters dated January 28, 2026. In terms of SEBI Master Circular no. SEBI/HO/DDHS/DDHS-PoD/P/CIR/2025/0000000137 dated October 15, 2025 (as amended), for issue and listing of Non-convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper, please be informed that the Company has fully bought-back and fulfilled its payment obligation in respect of the Commercial Papers (CPs) as per following details:

ISIN	Buyback Date	Date of Payment	Face Value of CP (Rs.)
INE376G14040	January 30, 2026	January 30, 2026	Rs. 1,800 Crores
INE376G14057	January 30, 2026	January 30, 2026	Rs. 200 Crores

Further, this is also to certify that:

1. The CPs were issued for the purposes mentioned in Annexure I and the CP proceeds were utilized for purposes disclosed therein and the Company is in adherence to other listing conditions as mentioned in the application for listing.
2. The other conditions of the offer document and the CP issuance directions are adhered to.
3. The asset classification of fund-based facilities from bank/Financial Institutions continued to be "Standard".



4. There has been no material change in our financial status adversely affecting the credit rating of the CPs.
5. The Buyback of the Commercial Papers have been done in accordance with the relevant guidelines issued by Fixed Income Money Market and Derivatives Association of India (FIMMDA).
6. The Company has received consent of the holders of the Commercial Papers for the Buyback.
7. The Company has made a full Buyback of the Commercial Papers.

We request you to take this on record.

Thanking You,

Yours faithfully,

For Biocon Limited

Rajesh U. Shanoy
Company Secretary and Compliance Officer
M. No.: ACS 16328

Encl. as above



Annexure – 1

Issuer Name	Date of issue of CP	ISIN No.	Units	End Use of Funds
Biocon Limited	22/12/2025	INE376G14040	36,000	Acquisition of equity shares in subsidiary
Biocon Limited	02/01/2026	INE376G14057	4,000	Redemption of debentures issued by company and acquisition of debentures issued by subsidiary.